You are here
- Home
- Research
- Our facilities
Mölndal, Sweden
Our R&D facility in Mölndal is situated just south of Gothenburg, the second largest city in Sweden.
Over 2,700 people work at this site where research is primarily focused on diseases of the gastrointestinal and cardiovascular systems, with a long-standing record of success including Losec (Prilosec), Seloken and Nexium.
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD - Stockholm
-
310.10 SEK
At 21-Nov-2009 02:22 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
